New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 18, 2014
08:52 EDTPTCTPTC Therapeutics price target raised to $43 from $34 at Roth Capital
Roth Capital increased its price target on PTC as the firm thinks that, based on recent favorable developments, the company's spinal muscular atrophy program is gaining steam. Roth believes that the compounds identified by PTC can be expanded to other neuro-muscular disorders. Roth reiterates a Buy rating on the stock.
News For PTCT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:08 EDTPTCTPTC Therapeutics Translarna granted orphan designation in U.S., EU
Subscribe for More Information
December 18, 2014
06:35 EDTPTCTPTC Therapeutics initiated with a Buy at Citigroup
Subscribe for More Information
December 12, 2014
12:02 EDTPTCTPTC Therapeutics Translarna granted orphan drug designation
Subscribe for More Information
December 9, 2014
12:15 EDTPTCTPTC Therapeutics mentioned positively by dealReporter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use